Atrix/Sanofi Leuprogel
Executive Summary
Sanofi-Synthelabo acquires rights to Atrix' Phase III prostate cancer treatment leuprolide for approximately $60 mil. The sum includes a down payment, a $15 mil. equity investment in Atrix, as well as future payments for regulatory and sales milestones. Atrix will receive royalty payments from product sales